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Objectives. Our recent experience with outpatient left ventric-
ular assist device (LVAD) support is presented to demonstrate the
possibilities and limitations of long-term outpatient mechanical
circulatory assistance.
Background. The experience with inpatient LVAD support as a
bridge to transplantation has proved the efficacy of such therapy
in improving circulatory hemodynamic status, restoring normal
end-organ function and facilitating patient rehabilitation. With
miniaturization of the power supplies and controllers, such me-
chanical circulatory support can now be accomplished in an
outpatient setting.
Methods. Between March 1993 and February 1997, 32 patients
(26 male, 6 female, mean [6SEM] age 49 6 15 years) underwent
implantation of the ThermoCardiosystems (TCI) Heartmate
vented electric (VE) LVAD. The VE LVAD is powered by batteries
worn on shoulder holsters and is operated by a belt-mounted
system controller, allowing unrestricted patient ambulation and
hospital discharge.
Results. Mean duration of support was 122 6 26 days (range 3
to 605), with a survival rate to transplantation or explantation of
78%. Nineteen patients were discharged from the hospital on
mean postoperative day 41 6 4 (range 17 to 68), for an outpatient
support time of 108 6 30 days (range 2 to 466). Four patients
underwent early transplantation and could not participate in the
discharge program, and three patients currently await discharge.
The complication rate was not statistically different from that
encountered in our previous 52 patients with a pneumatic LVAD.
Conclusions. Outpatient LVAD support is safe and provides
improved quality of life for patients awaiting transplantation.
Wearable and totally implantable LVADs should be studied as
permanent treatment options for patients who are not candidates
for heart transplantation.
(J Am Coll Cardiol 1997;30:1773–7)
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Despite improvements in survival with new medical therapeu-
tics, 60,000 patients will eventually develop congestive heart
failure unresponsive to any medical therapy (1). Although
heart transplantation is an effective treatment for end-stage
heart disease, the limited donor pool makes this an option for
only 2,500 patients/year (2). As such, heart transplantation has
only a trivial impact on the epidemiology of heart failure. In an
attempt to fill this void, alternatives to transplantation have
been sought, with mechanical circulatory assistance leading the
way.
Left ventricular assist devices (LVADs) have been widely
and successfully used in the short and medium term as a bridge
to transplantation. The now 8- to 10-year experience with
LVADs in this setting has established their efficacy in reestab-
lishing circulatory hemodynamic status and restoring normal
end organ function (3–5). Aggressive rehabilitation has al-
lowed most of these patients to return to New York Heart
Association functional class I heart failure before undergoing
heart transplantation (6,7). With the consolidation of the
power supplies and controllers, many of these systems have
become “wearable” (8,9), thus allowing unrestricted patient
ambulation and discharge from the hospital on mechanical
circulatory support while awaiting transplantation. Our recent
experience with outpatient LVAD support as a bridge to
transplantation and recovery is presented to demonstrate the
possibilities and limitations of long-term outpatient mechani-
cal circulatory assistance.
Methods
Device description. The ThermoCardiosystems (TCI)
Heartmate LVAD was implanted in all patients. This device
has a pusher-plate design with a stroke volume of 85 ml. The
inflow to the device is attached to the left ventricular apex by
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a Teflon sewing cuff, and a Dacron outflow graft is anasto-
mosed to the lateral portion of the ascending aorta. The inflow
and outflow conduits are guarded by 25-mm porcine valves
that ensure unidirectional flow. The device is implanted in a
properitoneal pocket in the left upper quadrant, and drivelines
exit the abdominal wall in the left lower quadrant (Fig. 1). The
interior, blood-contacting surface, is textured, promoting the
rapid ingrowth of a biologic lining composed of platelets,
endothelial-like cells, macrophages and lymphocytes (Fig. 2)
(10). This biologic pseudointima makes anticoagulation unnec-
essary in the majority of cases (11). The device is normally
operated in the automatic mode, which programs ejection
when the device is 95% full.
The earlier designs of the TCI LVAD were powered by
large pneumatic consoles that provided programmed pulses of
air to the air chamber of the device, which resulted in
displacement of the pusher plate upward and ejection of blood
into the aorta. The pneumatic design allowed for patient
ambulation and rehabilitation, but hospital discharge was not
possible because of the bulky console. The vented electric
(VE) design replaces the pneumatic chamber with an electri-
cally powered low-speed torque motor. The motor drives a pair
of cam-follower bearings, and as the rotor turns it displaces the
pusher plate upward. The VE power supply and controller
have been miniaturized, and a “wearable” system has been
designed (Fig. 1). Power can be supplied by two batteries that
can deliver up to 8 h of charge time and can be worn in two
shoulder holsters. The controller fits in the palm of one hand
and can be attached to a belt. The electrical driveline and a
pneumatic vent line exit from the skin, which has allowed for
unlimited patient ambulation with restriction only on activities
that might submerge the vent line, such as swimming or
bathing.
Three levels of fail safe rescue exist with the VE LVAD
should device malfunction occur: 1) The native heart usually
recovers enough function to keep the patient alive should no
pump function exist. 2) The electronic control unit is extracor-
poreal and allows damaged software, chip or electronic failures
to be easily fixed or replaced. 3) The pusher plate design allows
hand-held pneumatic actuation should the electric motor of
the device fail.
Selection criteria. Our criteria for LVAD implantation
have been outlined elsewhere (3,12), and similar indications
were used for implantation of the outpatient VE device.
Briefly, hemodynamic evidence of cardiogenic shock, including
a pulmonary capillary wedge pressure .20 mm Hg, and either
a cardiac index ,2.0 liters/min per m2 or a systolic blood
pressure ,80 mm Hg despite maximal inotropic support were
present in all patients. As with the earlier pneumatic experi-
ence, all eligible VE LVAD recipients were appropriate can-
didates for heart transplantation. Patients also had to have a
body surface area .1.5 m2 to accommodate the room neces-
sary for properitoneal device insertion. Finally, potential VE
recipients underwent a subjective assessment of their ability to
Abbreviations and Acronyms
LVAD 5 left ventricular assist device
RVAD 5 right ventricular assist device
TCI 5 ThermoCardiosystems
VE 5 vented electric
Figure 1. Schematic diagram of wearable VE LVAD. The device is
powered by batteries worn on two shoulder holsters. The system
controller fits in the palm of the hand and can be worn on a belt. A
driveline containing the electric cables and a vent line exit the skin.
Figure 2. Photograph of the opened VE LVAD revealing the blood-
contacting surfaces. The interior surfaces are textured, promoting the
formation of a biologic neointima and making anticoagulation unnec-
essary in the majority of cases.
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care for and manage the device. A 24-h companion capable of
operating and managing the device was likewise a prerequisite
for VE LVAD insertion.
Patients. Between March 1993 and February 1997, 32 VE
LVADs were implanted at our institution. The preoperative
characteristics of the VE LVAD recipients (6 female, 26 male;
mean [6SD] age 49 6 3 years) are shown in Table 1 and are
compared with the preoperative characteristics of our previous
52 pneumatic LVAD recipients. The youngest VE LVAD
recipient was 11 years old and the oldest was 65. The major
indications for VE LVAD insertion were ischemic cardiomy-
opathy (18 patients) and idiopathic dilated cardiomyopathy (11
patients). Of the patients with ischemic cardiomyopathy, three
had placement of the device in the setting of postcardiotomy
cardiogenic shock, and seven had incurred a myocardial infarc-
tion within 2 weeks of device placement.
Patient release protocol. With the institution of the VE
LVAD recipient discharge program in 1993, several Food and
Drug Administration (FDA) guidelines were established to
ensure patient psychological and physical readiness to be away
from medical personnel. These guidelines have been tailored
to individual patient needs over the past 4 years as our
experience with outpatient LVAD support has grown. In
general, most patients undergo intensive inpatient rehabilita-
tion and must be in functional class I before participating in the
discharge protocol. Echocardiographic evidence should exist
that the native heart can open the aortic valve when the LVAD
is set at its lowest rate, to ensure that the patient can
transiently maintain a blood pressure until manual pumping
can commence should the device fail. Finally, both patient and
a 24-h companion have to pass a training course on the use and
care of the device, with particular attention to emergency
interventions.
Once these general criteria are met, the patients undergo a
gradual four-phase program of hospital discharge that begins
with day trips lasting up to 16 h. On return to the hospital, both
patient and companion fill out questionnaires to assess both
compliance with device care and individual concerns and
questions regarding medical and device management. Once
several successful day trips are made, the patients are dis-
charged for up to 3 days at a time. On return to the hospital,
questionnaires again confirm compliance and identify potential
problems. Once these extended periods away from the hospital
are achieved successfully, the patients are fully discharged,
with weekly follow-up in the LVAD outpatient clinic.
Statistics. Results are presented as the mean value 6
SEM. Continuous variables were analyzed by the paired Stu-
dent t test. The Fisher exact test for 2 3 2 tables was used for
categoric variables. Analysis was considered significant at a p
value #0.05.
Results
Clinical outcome. The clinical outcome of the 32 VE LVAD
recipients is shown in Table 2 and is compared with that of the
previous 52 pneumatic LVAD recipients. Of the 32 VE LVAD
recipients, 20 have been bridged to transplantation, 1 has under-
gone explantation after 186 days of support, and 5 are currently
on device support, for an overall survival rate of 77%. The VE
LVAD recipients were supported for a mean of 122 6 26 days,
with the longest support times being 605, 541 and 412 days.
Of the 32 VE LVAD recipients, 4 underwent early heart
transplantation and were therefore not able to participate in
the discharge program. Of the remaining patients eligible for
discharge, 3 took day trips only, 3 remain in hospital awaiting
discharge, and 16 were fully discharged (Fig. 3). Most patients
were transferred from the acute care cardiac service to the
inpatient rehabilitation service within 30 days of implantation,
with the earliest transfer occurring on postoperative day 7. The
mean discharge day from the hospital was postoperative day
41 6 4 (range 17 to 69). Among the 19 patients discharged to
Table 1. Preoperative Characteristics of Patients Receiving
In-Hospital Pneumatic or Outpatient Vented Electric Devices*
Pneumatic
(n 5 52)
VE
(n 5 32)
Age (yr) 51 6 2 49 6 3
Range 13–65 11–65
Female 12 (23%) 6 (18%)
Indications for support
Ischemic CM 28 (54%) 18 (56%)
Idiopathic dilated CM 19 (37%) 11 (35%)
Myocarditis 4 (7%) 0 (0%)
Hypertrophic CM 1 (2%) 2 (6%)
Adriamycin-induced CM 0 (0%) 1 (3%)
*p 5 NS for all comparisons. Data presented are mean value 6 SEM, range
or number (%) of patients. CM 5 cardiomyopathy; VE 5 vented electric.
Table 2. Clinical Outcome of Patients Receiving Vented Electric
Outpatient Device Versus In-Hospital Pneumatic Device*
Pneumatic VE
Duration of support (days) 100 6 13 122 6 26
Range 0–363 3–605
Transplantation 34 (65%) 20 (72%)
Explantation 2 (4%) 2 (7%)
Overall survival rate 69% 79%
*p 5 NS for all comparisons. Data presented are mean value 6 SEM or
number (%) of patients, unless otherwise indicated. VE 5 vented electric.
Figure 3. Flowchart depicting the discharge disposition of 32 patients
undergoing outpatient VE LVAD implantation. Three patients took
day trips only, and 16 were fully discharged home.
1775JACC Vol. 30, No. 7 DEROSE ET AL.
December 1997:1773–7 OUTPATIENT LVAD SUPPORT
date, mean outpatient support has been 108 6 30 days. The
longest outpatient support times have been 466 days, 320 and
320 days. While discharged, patients have participated in a
wide range of activities, including showering, tennis, bicycling,
ballroom dancing and gardening. A majority of patients have
also reported resuming normal sexual activity, and many have
continued to work and attend school.
Complications. The complication rate among the VE
LVAD recipients was similar to that encountered among the
in-hospital pneumatic LVAD recipients (Table 3). Periopera-
tive right heart failure was defined as an indexed LVAD output
,1.8 liters/min per m2 in the setting of elevated central venous
pressure (.20 mm Hg) and a decompressed left ventricle and
occurred in 6 patients (19%). Right heart failure was managed
successfully with inhaled nitric oxide in four patients. Two
patients required the combination of inhaled nitric oxide and
temporary right ventricular assist device (RVAD) placement
in the immediate postoperative period. RVAD support time
was 4 and 13 days, respectively, and both patients survived to
heart transplantation. Device-related infection occurred in
eight patients (25%), for an incidence of 0.104/patient-month
of support, and included device endocarditis in two patients,
pocket infections in two and driveline infections in four.
Suppression of infection was achieved with antibiotics and
local wound care in five patients. Device infection necessitated
explantation in one patient, and two patients required myocu-
taneous advancement flap procedures to contain local infec-
tions. There were four graft-related hemorrhages (13%) (0.024
events/patient-month of support), resulting in one death. Of
the other three outflow graft holes, one occurred in the
intensive care unit and was emergently repaired without neu-
rologic sequelae. The other two were intermittent leaks that
were diagnosed at weekly follow-up and repaired semiurgently
without complication. The thromboembolism rate remained
low at 6% (0.015 events/patient-months of support), and there
were no embolic events in the outpatient setting. Of the two
embolic phenomena, one occurred in a patient who had a large
ventricular thrombus that was not appreciated by preoperative
transesophageal echocardiography. The second cerebral em-
bolism occurred in the setting of device endocarditis.
There were three device malfunctions that occurred after
prolonged support. One patient had bearing wear in the setting
of intermittent outflow graft obstruction, necessitating device
replacement and graft revision on day 270 of support. A second
patient had dislodgment of the pusher plate from the driver
cam, requiring device replacement on day 296 of support. A
third patient had malfunction of the cam position sensor in the
setting of bearing wear. This patient was admitted, and the LE
device was converted to a pneumatic console. He remained in
the hospital for 3 months until uneventful heart transplanta-
tion.
Six deaths occurred due to intraoperative air embolism on
day 3 of support, small bowel obstruction on day 11, intraop-
erative cerebral embolism on day 13, aortic tear on day 22,
multisystem organ failure on day 40 and gastrointestinal hem-
orrhage on day 100, respectively. All deaths occurred in the
hospital, none occurred in the outpatient setting.
Discussion
The inpatient bridge to transplantation experience has
established the efficacy of circulatory assistance in normalizing
hemodynamic status and restoring end-organ function (3–5).
The ability to participate in aggressive rehabilitation has
allowed patients to achieve higher functional class levels at the
time of transplantation (6,7). Given that indications for im-
plantation and patient selection were similar among VE
LVAD and pneumatic LVAD recipients in our series, it is not
surprising that identical benefits and survival statistics were
enjoyed among in-hospital and outpatient LVAD recipients.
The complications encountered in the VE LVAD cohort
were similar to those encountered in the pneumatic LVAD
recipients. Most complications were not unique to outpatient
LVAD support; rather, they were particular to mechanical
support in critically ill patients. Once patients were well
enough to be discharged from the hospital, few major compli-
cations occurred. After discharge, the most common reason for
a patient to contact the LVAD team was controller malfunc-
tion or alarm signaling, which frequently prompted evening or
emergent trips to the hospital, where interrogation of the
system pinpointed the problem. Replacement or adjustment of
the controller was usually sufficient, and patient lives were
never in danger.
Our experience with .2,140 days of outpatient support with
the VE LVAD has proved the reliability and safety of this
therapy. Multiple advantages of such support over inhospital
confinement exist. Both physical and psychological well-being
are markedly improved among patients who are discharged
from the hospital while awaiting transplantation. Among the
19 patients discharged from the hospital in this series, a
number of them continued to work and attend school. Patients
were able to shower and enjoy activities that included golf,
tennis, bicycle riding, gardening, softball and ballroom danc-
ing. Furthermore, almost all patients resumed sexual activity.
Table 3. Complications Among Patients Receiving Outpatient
Vented Electric Devices and Inpatient Pneumatic Devices
Pneumatic VE
p
Value
Intraoperative RVF 16 (30%) 8 (25%) NS
Inotropic support 11 2 NS
NO 3 6 NS
RVAD 4 2 NS
Graft-related
hemorrhage
4 (8%) 4 (13%) 0.06
0.024 pt-mo support 0.031 pt-mo support
Thromboembolism 3 (5.8%) 2 (6%) NS
0.017/pt-mo support 0.015/pt-mo support
Device-related
infection
18 (34%) 9 (28%) NS
0.104 pt-mo support 0.069 pt-mo support
Data presented are number (%) of patients, unless otherwise indicated.
RVF 5 right ventricular failure; NO 5 inhaled nitric oxide; pt 5 patient;
RVAD 5 right ventricular assist device; VE 5 vented electric.
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We recently (9) quantified this improvement in quality of
life with rating scales, including the Nottingham health profile
and the sickness impact profile. As early as 4 weeks after
discharge, patients showed an improvement in most areas of
quality of life examined. By 12 weeks after discharge, patients
showed a statistically significant improvement in all aspects of
quality of life. Similar findings have likewise been observed by
Kendall et al. (13) among inhospital pneumatic LVAD recip-
ients when preoperative quality of life measures were com-
pared with postoperative scores. In the present study, it is not
clear whether the major improvement in the sense of well-
being is secondary to LVAD support or hospital discharge.
However, of the in-hospital LVAD recipients studied by
Kendall et al. (13), the aspect of pneumatic mechanical
support that bothered patients most was confinement and
tethering of the device. Finally, in this era of cost containment,
outpatient LVAD support provides an alternative that is
markedly less expensive than either inpatient mechanical sup-
port or long-term inpatient inotropic support (14).
Given the safety and efficacy of outpatient support as a
bridge to transplantation, enthusiasm has grown for the use of
mechanical circulatory devices as a destination therapy for
end-stage heart disease. Debate still exists over whether wear-
able percutaneous systems or totally implantable systems will
provide the best option for permanent mechanical circulatory
support (15). The primary advantage of a percutaneous system
is the location of the majority of device hardware outside the
patient’s body, which provides several layers of fail safe
mechanisms should the device fail. However, that these devices
are partially externalized also makes them extremely suscepti-
ble to eventual infection. Less rigid drivelines with antibiotic
impregnation are currently being studied and may provide
protection against inevitable infection. Totally implantable
systems have the advantage of being completely contained
within the patient and are therefore less susceptible to direct
contamination. However, there are no fail safe mechanisms
should device failure ensue.
Despite the use of angiotensin-converting enzyme inhibi-
tors, the survival rate among subgroups of patients with
functional class IV heart failure remains no higher than 25% at
2 years (16). Given these dismal statistics, a National Institutes
of Health-sponsored, randomized trial (Randomized Evalua-
tion of Mechanical Assistance for the Treatment of Congestive
Heart Failure [REMATCH]) trial (8) has been established to
compare destination VE LVAD support with medical therapy
for patients with end-stage heart disease who are not consid-
ered candidates for transplantation.
Conclusions. Our short-term experience with the outpa-
tient VE LVAD is encouraging and makes aggressive pursu-
ance of the REMATCH trial imperative to assess whether
current technology will provide a valuable long-term alterna-
tive to medical management for end-stage heart disease.
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